Evidence map›Paper›PMID 42542537›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Glycoengineering of Monoclonal Antibodies with Homogeneous Glycan Isomers with Asymmetric Antennae.

Roger Y Tam, Grayson Hatfield, Lioudmila Tepliakova

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Roger Y TamRegulatory Research Division, Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada. roger.tam@hc-sc.gc.ca.
Grayson HatfieldRegulatory Research Division, Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.
Lioudmila TepliakovaRegulatory Research Division, Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylation is an important post-translational modification that can alter the biological activities of antibodies. In monoclonal antibody biotherapeutic products, glycosylation of the Fc-domain, which is often sensitive to manufacturing conditions, can alter product potency by affecting its interactions with host immune cells. Improving control of antibody glycosylation to produce more chemically defined products and to better understand glycan function is gaining interest, with chemoenzymatic glycan engineering emerging as a powerful technique. This chapter describes methods to obtain purified glycans, including isomers with asymmetric antennae, their enzymatic incorporation into monoclonal antibodies, and a natural killer T cell-based binding assay to determine FcγRIIIA (CD16A) binding affinity.

Indexed as

Antibodies, MonoclonalPolysaccharidesProtein EngineeringAnimalsFlow CytometryGlycosylationHumansIsomerismKiller Cells, NaturalReceptors, IgGAntibodies, MonoclonalPolysaccharidesReceptors, IgGChemoenzymatic synthesisFc-effector activitiesFlow cytometryGlycoengineeringMonoclonal antibodiesNK92-CD16A

Identifiers

PMID42542537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.